Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Advisor operating in the Biotechnology space. If you think a Advisor is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Andrew Rice
Scientific Advisor of Spinifex Pharmaceuticals
Andrew is Professor of Pain Research at Imperial College London and Honorary Consultant in Pain Medicine at Chelsea and Westminster Hospital. He undertakes research and clinical practice in neuropathic pain, focussing on post herpetic neuralgia, peripheral nerve injury and HIV neuropathy. Andrew received his medical degree from the St. Mary’s Hospital Medical School in 1982 and his research doctorate from the St. Thomas’ Hospital Medical School (UMDS) in 1991. He underwent his specialist clinical training mainly in Oxford and at St Thomas’ Hospital, London. He is an author of more than 90 scientific publications, sits on the editorial boards of Pain and PLoS–Medicine and is lead editor of the four volume “Textbook of Clinical Pain Management”. He is currently Chair-elect (previously Secretary) of the International Association for the Study of Pain Special Interest Group on Neuropathic Pain (www.neupsig.org). Andrew is Administrative Director of the Wellcome Trust funded London Pain Consortium (www.lpc.ac.uk) and the academic lead for the animal models work package on the EU Innovative Medicines Initiative grant “Europain”. He is also the link person between Europain and the corresponding US Food and Drugs Administration Critical Path Initiative: Analgesic Clinical Trial Innovations, Opportunities and Networks (ACTION). He was the Michael Cousins lecturer at the Australian and New Zealand College of Anaesthetists (2009) and Covino Lecturer at Harvard University (2008).Andrew led the protocol development team for the Phase 2 clinical trial of EMA401 in post herpetic neuralgia patients and, given his clinical leadership in the area of neuropathic pain, helps guide the overall development of EMA401.
Follow Andrew Rice:
About Chelsea and Westminster Hospital, Imperial College London, The London Pain Consortium: Spinifex Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of products for the treatment of pain.
Praveen Anand
Scientific Advisor of Spinifex Pharmaceuticals
Praveen is Professor of Clinical Neurology at Imperial College London, based at Hammersmith Hospital. His medical education was at the Universities of Oxford and Cambridge, UK, and post-graduate training was at the Hammersmith Hospital and the National Hospital for Neurology and Neurosurgery, Queen Square, London. His research focuses on pathophysiological and molecular mechanisms in the human sensory neuropathies and chronic pain syndromes. Collaborations with pharmaceutical companies are directed to translational projects and new techniques which bridge the gap between pre-clinical developments and successful clinical applications. The techniques of assessment have included contact heat evoked potentials (CHEPS) and molecular markers in skin biopsies. Clinical trials have been conducted using novel compounds for pain and nerve regeneration with several companies, including GlaxoSmithKline, Genentech, Roche, and Amgen. He has over 150 peer reviewed publications in journals including Nature, Nature Medicine, Nature Genetics, The Lancet, and Science.Praveen is conducting fundamental pharmacology studies on the AT2 receptor in human tissue as well as providing clinical leadership into the Phase 2 program for EMA401.
Follow Praveen Anand:
About Imperial College London: Spinifex Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of products for the treatment of pain.
Alan Naylor
Scientific Advisor of Spinifex Pharmaceuticals
Follow Alan Naylor:
About Pathios Therapeutics: Spinifex Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of products for the treatment of pain.
Kasper Kruse Petersen
Advisor of Airfinity
Follow Kasper Kruse Petersen:
About : Airfinity is a science information and analytics company
Chris Jones
Non Executive Director & Special Advisor of MediSieve
Chris Jones joined Elasmogen as Executive Chairman in 2016.
Follow Chris Jones:
About Elasmogen, MediSieve, Mologic: MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.
Debasish Talukdar
President, Global Head of Advisory of Prescient Healthcare Group
Follow Debasish Talukdar:
About Prescient Healthcare Group: Prescient Healthcare Group was founded in London in 1995, originally specializing in competitive insights.
Carl Sterritt
Strategic Advisor of Lunac Therapeutics
Follow Carl Sterritt:
About : Lunac Therapeutics is a UK-based drug discovery company.
David Barber
Senior Geospatial Advisor of Defence Science and Technology Lab(DSTL)
Follow David Barber:
About : Defence Science and Technology Laboratory is an executive agency of the Ministry of Defence of the United Kingdom.
Tony Sedgwick
Life Science Advisor of Blueberry Therapeutics
Tony Sedgwick is life Science Advisor at Blueberry Therapeutics.
Follow Tony Sedgwick:
About : Blueberry Therapeutics focuses on developing medicines for inflammatory and infectious diseases.
Bob Clay
Senior Regulatory Advisor of Precision Medicines
Bob has over 30 years experience in drug development at AstraZeneca, Pfizer, Wellcome & Zambon. Bob served as Vice President of Global Regulatory Affairs at AstraZeneca with responsibility for oncology, infection, and personalised healthcare. Bob supported the development and approval of 16 drugs including cancer medicines Lynparza, Iressa and Caprelsa. Bob received his degree in Pharmacy from the University of Bath, MSc in BioPharmacy from the University of London and an MBA from the Open University.
Follow Bob Clay:
About : Precision Medicines is dedicated to improving the lives of cancer patients through developing novel targeted medicines.
John Sinden
Senior Scientific Advisor of ReNeuron Group
John Sinden is the Senior Scientific Advisor of [ReNeuronGroup](https://www.crunchbase.com/organization/reneuron-group#/entity), a developer of stem cell therapies for a range of neurodegenerative diseases and other conditions. Sinden holds a bachelor’s degree in psychology from the University of Sydney and PhD in neuroscience from the University of Paris. Sinden is based in Guildford, United Kingdom.
Follow John Sinden:
About Glialign, ReNeuron Group: ReNeuron Group engages in R&D and the commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.
